Welcome to the Wyoming Chapter of the American College of Cardiology
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
For more information and to register, please visit: ACC Rockies Chapter Meeting 2026
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- TomorrowLAND: Does Intracoronary Nicorandil Prevent No-Reflow in STEMI Patients Undergoing PCI?Prolonged perfusion balloon predilation and intracoronary delivery of Nicorandil with the Rx Ryusei perfusion balloon did not significantly reduce slow-flow or no-reflow in patients presenting with STEMI undergoing primary PCI, according to findings from the TomorrowLAND trial presented at TCT 2026.
- LIPSIA-STRATEGY: Angiography-Derived vs. Wire-Based FFR to Guide RevascularizationAngiography-derived vessel fractional flow reserve (vFFR)-guided revascularization met the prespecified absolute criterion for noninferiority to wire-based FFR, according to results from the LIPSIA-STRATEGY trial presented at TCT 2026 and simultaneously published in JACC.
- SIRONA: Sirolimus- vs. Paclitaxel-Coated Balloon Angioplasty at 3 YearsComparing sirolimus-coated balloon (SCB) and paclitaxel-coated balloon (PCB) angioplasty in patients with symptomatic femoropopliteal artery disease, no differences in walking capacity and health-related quality of life were noted; however, freedom from clinically driven target-lesion revascularization (TLR) was higher in the SCB group, according to three-year results from the SIRONA trial, presented at TCT 2026 and […]
- SIMPLAAFY: Reduced-Dose NOACs, Aspirin Alone Noninferior to DAPT Following LAACReduced-dose non-vitamin K oral anticoagulants (NOACs) as well as aspirin alone were noninferior to dual antiplatelet therapy (DAPT) for a composite of adverse clinical outcomes through six months following left atrial appendage closure (LAAC), according to results from the SIMPLAAFY trial...
- CLASP II TR: TTVr With PASCAL System Improves Health Status in Patients With Symptomatic Severe TRAmong patients with symptomatic severe tricuspid regurgitation (TR), transcatheter tricuspid valve repair (TTVr) with the PASCAL system in addition to optimal medical therapy (OMT) showed significant improvement in health status at one year when compared to OMT alone and no significant difference in mortality or heart failure (HF) hospitalization...